The cationic lipid broadens the scope of LNP usage in various applications from prophylactic vaccines to therapeutic and oncology applications
Polyplus is introducing a novel cationic lipid for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development.
Referred to as LipidBrick IM21.7c, this cationic lipid broadens the scope of LNP usage in various applications from prophylactic vaccines to therapeutic and oncology applications.
LipidBrick IM21.7c overcomes current generation ionizable lipid challenges used in LNP’s, by enabling a wider in vivo biodistribution and decreasing accumulation in the liver. Proof of concept work has demonstrated that due to LipidBrick IM21.7c’s intrinsic properties in modulating the overall charge of LNP’s, it improves drug efficiency and formulation stability without safety issue.
LipidBrick IM21.7c is already used in jetMESSENGER and liposomal formulations for mRNA delivery
“Polyplus draws on over 20 years legacy in cationic polymer and lipid-based delivery systems for both in vitro and in vivo models to power mRNA therapeutics, said Mario Philips, CEO. “As we carry forward this legacy, we are working to ensure that our offer opens new possibilities to improve LNP formulation to meet the growing demand of the mRNA therapeutic market. LipidBrick IM21.7c is already used in jetMESSENGER and liposomal formulations for mRNA delivery, as a ready-to-use solution that requires no onsite formulation.”
“In addition, RNA vaccine producers are looking for lipids without intellectual property (IP) constraints. Polyplus has an independent IP on LipidBrick IM21.7c and its imidazolium family of cationic lipid which allows simpler and more cost-effective contracts for direct developers and manufacturers to leverage their offer,” Julien Depollier, Strategic Partnership Director commented.